Ask AI
ProCE Banner Activity

ClinicalThought Expert Office Hours Forum: Innovations in Pancreatic Cancer

Clinical Thought

Experts answer your questions related to the program, “The Art of Therapeutic Balance: Innovations in Pancreatic Cancer Across the Disease Continuum.” This social media forum provides you with ongoing access to experts for your questions and challenging cases throughout the certified life of this program.

Released: May 14, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education, in partnership with the Pancreatic Cancer Action Network (PanCAN).

ProCE Banner

Supporters

Supported by educational grants from Novocure and Revolution Medicines, Inc.

Novocure

Revolution Medicines, Inc.

Partners

Pancreatic Cancer Action Network (PanCAN)

ProCE Banner

Target Audience

This activity is designed for community oncologists, advanced practice providers, oncology nurses, pharmacists, and other healthcare professionals involved in the multidisciplinary care of patients with pancreatic cancer across all disease stages, aiming to improve frontline and later-line treatment outcomes.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess emerging biomarker and molecular profiling data to guide personalized treatment decisions that incorporate novel therapeutic modalities

  • Select frontline and subsequent therapies for pancreatic cancer using current clinical evidence and guideline-based criteria, tailored to disease stage, patient performance status, and molecular biomarker profiles

  • Implement practical dose modification, toxicity monitoring, and supportive care strategies to manage gastrointestinal, hematologic, and neuropathic adverse events associated with pancreatic cancer therapies

Disclosure

Primary Author

Efrat Dotan, MD, MTR: consultant/advisor/speaker: AbbVie, Amgen, Jazz, Lutris, Merck, Merus; researcher: AstraZeneca, Bristol Myers Squibb, Ipsen.

Andrew H. Ko, MD, FASCO: researcher: Apexigen, Arcus, Astellas, Bristol Myers Squibb, Crystal Genomic, Leap Therapeutics, Novartis, Revolution Medicines, Roche/Genentech, Verastem; consultant/advisor/speaker: Astellas, Corcept, Gilead, Jazz, Legend Biotech, Merus, Pfizer, Renovo, Revolution Medicines, Tango Therapeutics.

Paul E. Oberstein, MD, MS: consultant/advisor/speaker: Ipsen, Lilly, Revolution Medicine, Tango Therapeutics.